Sugi Predict

Sugi Predict / Targets / TOP2A

TOP2A

DNA topoisomerase 2-alpha · P11388 · TOP2A on Sugi Atlas →

84,713 patent compounds predicted against TOP2A, 53,410 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tosufloxacin Tosufloxacin (SCHEMBL34354) 0.52 13/20
Tosufloxacin Tosufloxacin (SCHEMBL34355) 0.52 13/20
Losoxantrone Losoxantrone (SCHEMBL61319) 1.00 10/20
Losoxantrone Losoxantrone (SCHEMBL5170) 0.96 10/20
Clinafloxacin Clinafloxacin (SCHEMBL33959) 0.56 9/20
Clinafloxacin Clinafloxacin (SCHEMBL33960) 0.56 9/20
Clinafloxacin Clinafloxacin (SCHEMBL193233) 0.55 9/20
Clinafloxacin Clinafloxacin (SCHEMBL193234) 0.55 9/20
Purpurin Purpurin (SCHEMBL33871) 0.53 8/20
Ibafloxacin Ibafloxacin (SCHEMBL154637) 0.51 8/20
SCHEMBL143295 SCHEMBL143295 0.60 7/20
SCHEMBL116806 SCHEMBL116806 0.52 7/20
SCHEMBL143404 SCHEMBL143404 0.52 7/20
SCHEMBL116358 SCHEMBL116358 0.51 7/20
SCHEMBL116006 SCHEMBL116006 0.50 7/20
SCHEMBL116198 SCHEMBL116198 0.49 7/20
SCHEMBL115020 SCHEMBL115020 0.49 7/20
SCHEMBL145406 SCHEMBL145406 0.49 7/20
SCHEMBL146315 SCHEMBL146315 0.49 7/20
SCHEMBL116545 SCHEMBL116545 0.49 7/20

Clinical trials — most relevant to TOP2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer PHASE3COMPLETED
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML PHASE3UNKNOWN
A Study of Children With Refractory or Relapsed ALL PHASE3COMPLETED
Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases PHASE2UNKNOWN
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients PHASE1/PHASE2COMPLETED
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery PHASE2UNKNOWN
Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer PHASE2COMPLETED
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) PHASE2COMPLETED
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix PHASE2UNKNOWN
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications PHASE1/PHASE2RECRUITING
Topotecan for Irinotecan-Refractory SCLC PHASE2UNKNOWN
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers PHASE1/PHASE2COMPLETED
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma PHASE1/PHASE2NOT_YET_RECRUITING
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma PHASE2NOT_YET_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas PHASE1COMPLETED
Clinical Benefit of Topoisomerase Downregulation PHASE1COMPLETED
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer PHASE1COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer PHASE1ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors PHASE1COMPLETED
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia PHASE1COMPLETED
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer EARLY_PHASE1UNKNOWN
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer nanCOMPLETED
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer nanCOMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TOP2A binder may also engage these)

ProteinNameSimilarity
O46374 — 1.000 O46374 →
O42131 — 1.000 O42131 →
Q64511 — 1.000 Q64511 →
O42130 — 1.000 O42130 →
Q01320 — 1.000 Q01320 →
P41515 — 1.000 P41515 →
TOP2B DNA topoisomerase 2-beta 1.000 landscape →
P41516 — 1.000 P41516 →
Q64399 — 1.000 Q64399 →
P15348 — 1.000 P15348 →
Q23670 — 1.000 Q23670 →
O16140 — 1.000 O16140 →
P06786 — 0.998 P06786 →
P08096 — 0.997 P08096 →
P87078 — 0.996 P87078 →
O24308 — 0.996 O24308 →
O93794 — 0.996 O93794 →
Q01879 — 0.996 Q01879 →
P30182 — 0.994 P30182 →
Q9Y8G8 — 0.993 Q9Y8G8 →
G5ECQ8 — 0.991 G5ECQ8 →
NAT10 RNA cytidine acetyltransferase 0.989 landscape →
Q55BP5 — 0.989 Q55BP5 →
Q54V77 — 0.989 Q54V77 →
P41001 — 0.988 P41001 →
P53914 — 0.988 P53914 →
O87545 — 0.988 O87545 →
P34534 — 0.987 P34534 →
O50627 — 0.987 O50627 →
P94604 — 0.987 P94604 →